RenovoRx (RNXT) Net Cash Flow (2020 - 2026)
RenovoRx (RNXT) posted Net Cash Flow of $5.3 million for Q1 2026, up 276.75% sequentially from -$3.0 million in Q4 2025, and down 28.14% YoY from $7.4 million in Q1 2025.
RenovoRx (RNXT) Net Cash Flow (2020 - 2026) Analysis & Trends
RenovoRx has reported Net Cash Flow for 7 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Net Cash Flow fell 28.14% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 million (down 121.75% YoY) and the FY2025 annual result came in at -$130000.0, down 102.17% from the prior year.
- Net Cash Flow advanced to $5.3 million in Q1 2026 per RNXT's latest filing, from -$3.0 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $7.4 million in Q1 2025 and troughed at -$3.0 million in Q4 2025.
- A 5-year average of $304823.5 and a median of -$2.1 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow slumped 941.98% in 2023, then jumped 581.44% in 2024.
- Over 5 years, Net Cash Flow stood at $1.3 million in 2022, then slumped by 258.17% to -$2.1 million in 2023, then dropped by 16.76% to -$2.4 million in 2024, then decreased by 25.99% to -$3.0 million in 2025, then jumped by 276.75% to $5.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $5.3 million, -$3.0 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | -2.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.88 Mn |
| Jun 30, 2026 | -2.88 Mn |
| Mar 31, 2026 | 5.34 Mn |
| Mar 31, 2026 | 5.34 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Sep 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | 7.43 Mn |
| Mar 31, 2025 | 7.43 Mn |
| Dec 31, 2024 | -2.40 Mn |
| Dec 31, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.18 Mn |
| Sep 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | 7.35 Mn |
| Jun 30, 2024 | 7.35 Mn |
| Mar 31, 2024 | 3.22 Mn |
| Mar 31, 2024 | 3.22 Mn |